Success Rates for Appeals of Denied Prescription Drug Coverage in U.S. Health Insurance

Health insurance denials for prescription medications—particularly those deemed "no longer covered" due to changes in formulary lists, prior authorization failures, or exclusions—are a growing frustration for millions of Americans. These denials often stem from cost-control measures by insurers, such as shifting drugs to higher tiers or removing them entirely from coverage. While exact statistics tailored to "no longer covered" medications are limited (as insurers rarely break out denial reasons in public data), broader data on prescription drug coverage appeals provides a reliable proxy. This is because most such denials fall under categories like "service not covered" (16% of all denials) or lack of prior authorization (14%), both of which are commonly appealed and overturned at similar rates.

Based on analyses from sources like the Kaiser Family Foundation (KFF), the American Medical Association (AMA), and the Centers for Medicare & Medicaid Services (CMS), the percentage of appeals that are ultimately won by the policyholder (i.e., the denial is overturned, leading to full or partial coverage) ranges from 40% to 83%, depending on the insurance type, appeal level, and whether it's an internal (insurer-reviewed) or external (independent) process. However, a key caveat: Only about 1% of denials are ever appealed, largely due to complexity, time constraints, and lack of awareness. This low appeal rate means billions in potential coverage go unclaimed annually.

Breakdown by Insurance Type and Appeal Stage

Success rates vary by payer and process stage. Internal appeals (filed directly with the insurer) have lower win rates than external ones, but many denials are overturned early via resubmissions or peer-to-peer reviews. For prescription drugs specifically, appeals often succeed when supported by a prescriber's letter demonstrating medical necessity or alternatives' inadequacy.

Notes: Win rates include full/partial coverage approvals. Data from 2014-2023; recent trends show rising denials (19% of in-network claims in 2023, up from 17% in 2021) but stable appeal success. Prescription-specific denials rose 25% from 2016-2023, often due to pharmacy benefit manager (PBM) decision

Why the Wide Range? Factors Influencing Success

• Appeal Type: Prior authorization (PA) appeals for drugs—common when a med is "no longer covered"—have the highest success (80%+ in MA), as they often involve clear medical necessity evidence. Post-service claims (after filling the prescription) succeed less (~40%) due to stricter documentation needs.
• Evidence Strength: Wins jump with a doctor's letter (e.g., explaining why alternatives fail) or peer-to-peer review; 62% of denials are overturned with resubmissions alone.
• Insurer Practices: Companies like UnitedHealthcare deny ~32% of claims (highest rate), but appeals succeed ~50% against them. Medicare plans overturn more (75-83%) to comply with federal rules.
• Demographics: Lower-income or minority patients win less often due to barriers like time or knowledge gaps.

The Bigger Picture: Low Appeal Rates Hide High Potential Wins

Despite strong odds, <1% of the ~73 million annual denials (including 19% of in-network drug claims) are appealed, costing patients $20B+ out-of-pocket. Reasons include intimidation (80% of denied patients find insurance "hard to understand") and delays (30-72 days for decisions). Providers spend $19.7B yearly on appeals, with 54% success but high admin costs ($44/claim).

For "no longer covered" drugs, request a formulary exception first—success mirrors PA appeals (80%+ with evidence). Tools like state Consumer Assistance Programs (CAPs) boost wins by 20-30%.

In summary, if you appeal a denial for a medication no longer covered, your odds of winning are typically 50-80%, far better than the <1% who try. So, put in that appeal - with most insurers it's as simple as calling their customer service number and starting an inquiry. Start with your denial notice's instructions, file the appeal for the denial, and escalate to external review if needed. Resources: HealthCare.gov appeals guide or Medicare.

References -

American Medical Association (AMA) Analysis (2024): Reports that over 80% of prior authorization appeals for denied treatments—including medications—result in approval upon appeal, based on KFF data from 2022. Link: https://www.ama-assn.org/practice-management/prior-authorization/over-80-prior-auth-appeals-succeed-why-aren-t-there-more

Health Policy Today (2025): Cites an 80% success rate for patient appeals of insurance claim denials, including those for non-covered medications, emphasizing the value of appealing despite low appeal volumes. Link: https://healthpolicytoday.org/2025/04/15/why-patients-should-appeal-a-denied-claim/

KFF Health News (2025): Indicates that nearly three-quarters (75%) of appealed health insurance claim denials—covering prescription drugs among other services—are overturned in favor of the patient. Link: https://kffhealthnews.org/morning-breakout/health-insurance-customers-who-appeal-their-claims-often-win/

Administration for Community Living (ACL) Advocate's Guide to Appealing Prescription Drug Denials (2023): States that nearly three-quarters (75%) of appealed prescription drug denials, including off-formulary cases where meds are no longer covered, are overturned or partially overturned at the plan level. Link: https://pfs2.acl.gov/strapib/assets/Part_D_Appeals_Ch_Summary_c5932829ab.pdf

Kaiser Family Foundation (KFF) Report on Medicare Advantage (2024): Finds that more than 80% of prior authorization appeals for services like medications are successful, with a specific overturn rate of 82% in 2022 data. Link: https://www.darkdaily.com/2024/09/11/kaiser-family-foundation-reports-on-prior-authorization-denial-rates-by-medicare-advantage-plans/